A New Triphasic Oral Contraceptive PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download A New Triphasic Oral Contraceptive PDF full book. Access full book title A New Triphasic Oral Contraceptive by Ronald T. Burkman. Download full books in PDF and EPUB format.
Author: Ronald T. Burkman
Publisher:
ISBN:
Category : Oral contraceptives
Languages : en
Pages : 52
Get Book Here
Book Description
Author: Ronald T. Burkman
Publisher:
ISBN:
Category : Oral contraceptives
Languages : en
Pages : 52
Get Book Here
Book Description
Author: R.B. Greenblatt
Publisher: Springer Science & Business Media
ISBN: 9401166668
Category : Medical
Languages : en
Pages : 125
Get Book Here
Book Description
R.B. GREENBLATT The original oral contraceptives contained more oestrogen in the form of ethinyloestradiol or mestranol and progestagen in the form of norethynodrel or norethisterone than was necessary f(x conception control. There has been a trend over the years to reduce dosages of both components in order to minimize side eHects while ensuring eflcctiveness. However, as dosages were lowered, there has been an increase in spotting and break through bleeding during the first few months of their adminis tration. The sequential pill appeared more physiological in that it followed more closely physiological principles, but the need to employ large doses ofEE or EE3ME to inhibit O\'ulation and the higher pregnancy rate made the sequential regimen less attrac ti\'e or useful. A triphasic formulation has become available that takes advantage of the synergism between ethinyloestradiol and the potent levonorgestrel so that low doses of the oestrogen and very low doses of the progestagen could be employed with great effectiveness. Such a preparation is relatively free from side effects, partly because the basic pharmacological tenet of the minimal dose for the desired result and the division of'the cycle into three parts using 30,lIg ofEE for the first 6 days, then:) days of 40,lIg, followed by 30,fIg for 10 da ys, for a total of21 days, thus more or less mimicking the physiological rise and fall of 125 THE DEVELOP:'IE:-;T OF, \ :-;E\\' TRIPH. \SIC OR.
Author: R. B. Greenblatt
Publisher:
ISBN: 9789401166676
Category :
Languages : en
Pages : 132
Get Book Here
Book Description
Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692
Get Book Here
Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Author: I. A. Brosens
Publisher:
ISBN:
Category : Oral contraceptives
Languages : de
Pages : 76
Get Book Here
Book Description
Author: Melinda Wallach
Publisher:
ISBN: 9780965174527
Category : Medical
Languages : en
Pages : 308
Get Book Here
Book Description
Author: Eric J. Bieber
Publisher: Cambridge University Press
ISBN: 1107040396
Category : Medical
Languages : en
Pages : 1127
Get Book Here
Book Description
Written with the busy practice in mind, this book delivers clinically focused, evidence-based gynecology guidance in a quick-reference format. It explores etiology, screening, tests, diagnosis, and treatment for a full range of gynecologic health issues. The coverage includes the full range of gynecologic malignancies, reproductive endocrinology and infertility, infectious diseases, urogynecologic problems, gynecologic concerns in children and adolescents, and surgical interventions including minimally invasive surgical procedures. Information is easy to find and absorb owing to the extensive use of full-color diagrams, algorithms, and illustrations. The new edition has been expanded to include aspects of gynecology important in international and resource-poor settings.
Author: Cynthia Anne Graham
Publisher:
ISBN:
Category : Oral contraceptives
Languages : en
Pages : 384
Get Book Here
Book Description
"Two studies are presented which investigated the relationship between oral contraceptives (o.c.s) and premenstrual changes in mood and physical state. The retrospective pilot study examined possible differences in symptom-reporting between groups of pill-users and non-users. Women using o.c.s had lower severity scores on a number of physical and mood-related symptoms compared to non-users. In the prospective study, eighty-two women with complaints of moderate to severe premenstrual symptoms were recruited for a double-blind, controlled trial of a triphasic o.c. Subjects made daily ratings of symptoms for one to two baseline cycles and were then randomly assigned to receive either placebo or the o.c. for three treatment cycles. Prospective assessment of symptoms was made using a variety of measures, and circulating levels of estrogen and progesterone were measured at three points during the cycle. Bloating and breast pain showed a greater reduction in the o.c. group than in the placebo group. In a subgroup of women with premenstrual depressive change, the o.c. also produced greater improvement in a number of symptoms compared to placebo. For all other symptoms, there was no beneficial effect of the active treatment over placebo. Women who received o.c.s reported decreased sexual interest after starting the pill. Possible hormonal mechanisms for these effects are discussed." --
Author: A. A. Haspels
Publisher: Springer Science & Business Media
ISBN: 9401166757
Category : Medical
Languages : en
Pages : 220
Get Book Here
Book Description
A. A. Haspe/s It is with pleasure that I welcome you, on behalf of Professor Rolland and myself, to Amsterdam for this International Symposium on 'Benefits and Risks of Hormonal Contraception'. As a means offamily planning the pill is about 25 years old - a timespan which has been characterized by an enormous increase in public interest and concern with family health and family-planning. Undoubtedly we have learned a lot over the last 25 years. As you see in Figure 1, in the seventies in Holland relatively more fertile women used the pill than in any other country in the world. In 1974 new combination pills were introduced containing less than 50 JAg of ethinyl estradiol. In 1981 50 % of Dutch pill users took a sub-50 (Figure 2). The same is true for the Scandi navian countries. In our own University Clinic 95 % of pill-users take a sub-50 pill; only 5 % use a 50 JAg pill on medical indication. This decrease in estrogen dosage, which is usually accompanied by a decrease of progestational component as well, has resulted in a decrease of thromboembolic disease. Factors that are still important to consider are diabetes mellitus, hypertension, adipositas and smoking. Good selection of patients together with the prescribing where possible of sub-50 pills may result in the numbers of compli cations and side-effects being close to those encountered in the control group.
Author: Anthony C. Hackney
Publisher: Springer
ISBN: 3319445588
Category : Medical
Languages : en
Pages : 320
Get Book Here
Book Description
It is well-established, through extensive peer-reviewed published research, that physical activity and exercise training can impact the reproductive endocrine system of women. This ground-breaking, comprehensive title presents a range of unique insights into the opposite question: how the reproductive endocrine system of women affects their exercise ability. More precisely, the thematic question explored in this work is: if exercise affects reproductive hormones, conversely then could the reproductive hormones have physiological effects unrelated to reproduction that influence the capacity of women to exercise? In exploring this question, the goal is to better understand the unique physiology of women and whether female sex hormones might account for some of the variance in physiological performance between amenorrheic and eumenorrheic women, and within women across the age span as they experience menarche to menopause. Sex Hormones, Exercise and Women: Scientific and Clinical Aspects synthesizes the research by exploring the physiology and psychology behind these occurrences. This novel title will not only be of interest to researchers, exercise scientists, graduate students, and clinicians; it will also serve as a source of valuable information for female athletes and their trainers in the context of preparing for competitions.
